172 related articles for article (PubMed ID: 3156662)
1. Positron emission tomography in movement disorders.
Martin WR
Can J Neurol Sci; 1985 Feb; 12(1):6-10. PubMed ID: 3156662
[TBL] [Abstract][Full Text] [Related]
2. Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography.
Leenders KL; Frackowiak RS; Quinn N; Marsden CD
Mov Disord; 1986; 1(1):69-77. PubMed ID: 2973559
[TBL] [Abstract][Full Text] [Related]
3. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography.
Leenders KL; Palmer AJ; Quinn N; Clark JC; Firnau G; Garnett ES; Nahmias C; Jones T; Marsden CD
J Neurol Neurosurg Psychiatry; 1986 Aug; 49(8):853-60. PubMed ID: 3091770
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiology of movement disorders studied using PET.
Leenders KL
J Neural Transm Suppl; 1997; 50():39-46. PubMed ID: 9120423
[TBL] [Abstract][Full Text] [Related]
5. The role of positron emission tomography imaging in movement disorders.
Bohnen NI; Frey KA
Neuroimaging Clin N Am; 2003 Nov; 13(4):791-803. PubMed ID: 15024962
[TBL] [Abstract][Full Text] [Related]
6. PET and movement disorders.
Brooks DJ; Frackowiak RS
J Neurol Neurosurg Psychiatry; 1989 Jun; Suppl(Suppl):68-77. PubMed ID: 2666580
[TBL] [Abstract][Full Text] [Related]
7. [Functional neuroimaging in movement disorders].
Borbély K
Orv Hetil; 2001 Oct; 142(43):2347-55. PubMed ID: 11760452
[TBL] [Abstract][Full Text] [Related]
8. Cerebral glucose and dopa metabolism in movement disorders.
Martin WR; Hayden MR
Can J Neurol Sci; 1987 Aug; 14(3 Suppl):448-51. PubMed ID: 2960430
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography (PET) in "pure akinesia".
Taniwaki T; Hosokawa S; Goto I; Fujii N; Otsuka M; Kuwabara Y; Ichiya Y; Hasuo K; Kato M
J Neurol Sci; 1992 Jan; 107(1):34-9. PubMed ID: 1578232
[TBL] [Abstract][Full Text] [Related]
10. Cerebral blood flow and oxygen metabolism measurement with positron emission tomography in Parkinson's disease.
Leenders KL; Wolfson L; Jones T
Monogr Neural Sci; 1984; 11():180-6. PubMed ID: 6610825
[No Abstract] [Full Text] [Related]
11. Neurodegenerative movement disorders: the contribution of functional imaging.
Piccini P
Curr Opin Neurol; 2004 Aug; 17(4):459-66. PubMed ID: 15247543
[TBL] [Abstract][Full Text] [Related]
12. Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications.
Kuriakose R; Stoessl AJ
Prog Brain Res; 2010; 184():177-92. PubMed ID: 20887875
[TBL] [Abstract][Full Text] [Related]
13. PET measurements of dopaminergic pathways in the brain.
Perlmutter JS; Moerlein SM
Q J Nucl Med; 1999 Jun; 43(2):140-54. PubMed ID: 10429509
[TBL] [Abstract][Full Text] [Related]
14. Positron emission tomography and central neurotransmitter systems in movement disorders.
Weeks RA; Brooks DJ
Fundam Clin Pharmacol; 1994; 8(6):503-17. PubMed ID: 7721227
[TBL] [Abstract][Full Text] [Related]
15. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia.
Meyer-Lindenberg A; Miletich RS; Kohn PD; Esposito G; Carson RE; Quarantelli M; Weinberger DR; Berman KF
Nat Neurosci; 2002 Mar; 5(3):267-71. PubMed ID: 11865311
[TBL] [Abstract][Full Text] [Related]
16. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
[TBL] [Abstract][Full Text] [Related]
17. Dopaminergic dysfunction in midbrain dystonia: anatomoclinical study using 3-dimensional magnetic resonance imaging and fluorodopa F 18 positron emission tomography.
Vidailhet M; Dupel C; Lehéricy S; Remy P; Dormont D; Serdaru M; Jedynak P; Veber H; Samson Y; Marsault C; Agid Y
Arch Neurol; 1999 Aug; 56(8):982-9. PubMed ID: 10448804
[TBL] [Abstract][Full Text] [Related]
18. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
[TBL] [Abstract][Full Text] [Related]
19. Neurochemical anatomy of movement disorders.
Young AB; Penney JB
Neurol Clin; 1984 Aug; 2(3):417-33. PubMed ID: 6152481
[TBL] [Abstract][Full Text] [Related]
20. Chapter 33: the history of movement disorders.
Lanska DJ
Handb Clin Neurol; 2010; 95():501-46. PubMed ID: 19892136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
